Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjogren's Syndrome

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjogren's Syndrome

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seletalisib (Primary)
  • Indications Sjogren's syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors UCB

    • Most Recent Events

    • 19 Sep 2020 Primary endpoint (Change from Baseline to Week 12 in the European League Against Rheumatism Sjgrens Syndrome Disease Activity Index (ESSDAI)) has not been met, as per results presented at the 20th Annual Congress of the European League Against Rheumatism
    • 19 Sep 2020 Results published in the Rheumatology
    • 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top